Biopharmaceutical company Nanolek has completed the third stage of deliveries of the combined vaccine Pentaxim, indicated for the prevention of five infections, under a government contract.

From January through the end of March, a total of 913,000 doses of the vaccine were supplied to the regions of the Russian Federation. The deliveries were completed ahead of schedule - one month earlier than the contractual deadline. Distribution to the constituent entities of the Russian Federation was carried out in accordance with allocations approved by the Russian Ministry of Health.

The deliveries are being made under the government contract to meet the needs of the National Immunization Schedule in 2026.

“We consistently fulfill our commitments and ensure stable vaccine supplies to the regions. Early delivery supports timely vaccine availability and is an important factor in maintaining the stability of the national immunization system. The total volume of Pentaxim deliveries under the contract this year exceeds 4.7 million doses, which will be shipped to the regions in stages throughout the year, with some deliveries to be completed in early 2027,” said Nanolek CEO Evgeny Barinov.

The vaccine is intended for immunization of young children and is one of the core vaccines included in the National Immunization Schedule. It is administered at multiple stages during the first years of life and provides protection against several socially significant infections, forming the foundation of children’s immune protection. Since 2022, Pentaxim has been produced in Russia at the finished dosage form stage by Nanolek in partnership with Sanofi.

The next stage of deliveries under the contract is scheduled to begin in May 2026.